Similar articles for PMID: 15380186

Year	Number of Results
1958	1
1979	1
1988	1
1989	1
1990	2
1991	1
1992	3
1993	1
1994	1
1995	1
1996	4
1998	1
1999	2
2000	1
2001	2
2002	2
2003	6
2004	9
2005	10
2006	8
2007	7
2008	8
2009	7
2010	2
2011	1
2012	1
2013	1
2014	4
2016	3
2017	1
2019	1
2020	4
2021	2
2024	0

1

Simplified analogs of bryostatin with anticancer activity display greater potency for translocation of PKCdelta-GFP.

Baryza JL, Brenner SE, Craske ML, Meyer T, Wender PA. Baryza JL, et al. Chem Biol. 2004 Sep;11(9):1261-7. doi: 10.1016/j.chembiol.2004.06.014. Chem Biol. 2004. PMID: 15380186

2

The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: dissociation of activities using 26-epi-bryostatin 1.

Szallasi Z, Du L, Levine R, Lewin NE, Nguyen PN, Williams MD, Pettit GR, Blumberg PM. Szallasi Z, et al. Cancer Res. 1996 May 1;56(9):2105-11. Cancer Res. 1996. PMID: 8616857

3

Structural modifications of bryostatin 2.

Pettit GR, Sengupta D, Blumberg PM, Lewin NE, Schmidt JM, Kraft AS. Pettit GR, et al. Anticancer Drug Des. 1992 Apr;7(2):101-14. Anticancer Drug Des. 1992. PMID: 1575884

4

Identification of a tunable site in bryostatin analogs: C20 Bryologs through late stage diversification.

Wender PA, Baryza JL. Wender PA, et al. Org Lett. 2005 Mar 17;7(6):1177-80. doi: 10.1021/ol0501931. Org Lett. 2005. PMID: 15760168

5

In vivo administration of the anticancer agent bryostatin 1 activates platelets and neutrophils and modulates protein kinase C activity.

Berkow RL, Schlabach L, Dodson R, Benjamin WH Jr, Pettit GR, Rustagi P, Kraft AS. Berkow RL, et al. Cancer Res. 1993 Jun 15;53(12):2810-5. Cancer Res. 1993. PMID: 8504423

6

Synthesis of a simplified bryostatin C-ring analogue that binds to the CRD2 of human PKC-alpha and construction of a novel BC-analogue by an unusual Julia olefination process.

Hale KJ, Frigerio M, Manaviazar S, Hummersone MG, Fillingham IJ, Barsukov IG, Damblon CF, Gescher A, Roberts GC. Hale KJ, et al. Org Lett. 2003 Feb 20;5(4):499-502. doi: 10.1021/ol027392u. Org Lett. 2003. PMID: 12583753

7

Total synthesis and initial biological evaluation of new B-ring-modified bryostatin analogs.

Wender PA, Horan JC, Verma VA. Wender PA, et al. Org Lett. 2006 Nov 9;8(23):5299-302. doi: 10.1021/ol0620904. Org Lett. 2006. PMID: 17078702

8

The design, computer modeling, solution structure, and biological evaluation of synthetic analogs of bryostatin 1.

Wender PA, DeBrabander J, Harran PG, Jimenez JM, Koehler MF, Lippa B, Park CM, Siedenbiedel C, Pettit GR. Wender PA, et al. Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6624-9. doi: 10.1073/pnas.95.12.6624. Proc Natl Acad Sci U S A. 1998. PMID: 9618462 Free PMC article.

9

Role of the A-ring of bryostatin analogues in PKC binding: synthesis and initial biological evaluation of new A-ring-modified bryologs.

Wender PA, Clarke MO, Horan JC. Wender PA, et al. Org Lett. 2005 May 12;7(10):1995-8. doi: 10.1021/ol0504650. Org Lett. 2005. PMID: 15876038

10

A simple analogue of tumor-promoting aplysiatoxin is an antineoplastic agent rather than a tumor promoter: development of a synthetically accessible protein kinase C activator with bryostatin-like activity.

Nakagawa Y, Yanagita RC, Hamada N, Murakami A, Takahashi H, Saito N, Nagai H, Irie K. Nakagawa Y, et al. J Am Chem Soc. 2009 Jun 10;131(22):7573-9. doi: 10.1021/ja808447r. J Am Chem Soc. 2009. PMID: 19449873

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

92 results

Results by year